{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:14:47Z","timestamp":1788441287194,"version":"build-2803163510"},"reference-count":44,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alpha Psychiatry"],"abstract":"<jats:p>Background:In patients undergoing detoxification for benzodiazepine (BZD) dependence, withdrawal symptoms frequently persist into the low-concentration phase following drug discontinuation. Prolonged drug elimination may extend the duration of required medical supervision. Because lipophilic BZDs can accumulate in adipose tissue and be released gradually during detoxification, overweight patients may experience delayed elimination. This study quantitatively examined whether BZD elimination and the duration of withdrawal symptoms are prolonged in overweight patients.Methods:From 508 records of concentration-monitored detoxification, a retrospective sample of 290 inpatients matched for diet and physical activity was selected. All patients underwent detoxification according to the SAER protocol (Satiation, Anti-accumulation paradigm, Elimination, and Readaptation). Following (S) satiation with diazepam, further unnecessary (A) accumulation was prevented through aggressive day-by-day dose reductions guided by serum concentration monitoring. Subsequent tapering, leading to effective (E) elimination, was adjusted according to the evolving intensity of withdrawal symptoms, characterized by episodes of peak severity (withdrawal crises) interspersed with periods of relative relief. Completion of (R) readaptation was defined by the cessation of withdrawal symptoms after elimination. The duration of effective elimination, from peak serum concentration to undetectable levels, with particular attention to the post-discontinuation phase, was recorded. Concomitant medications known to influence BZD elimination were identified. Elimination parameters and the timing of clinically significant withdrawal crises were analyzed in relation to patients' body mass index (BMI).Results:Elimination duration was positively correlated with BMI (\u03c1 = 0.39, p &lt; 0.001). The timing of the strongest and\/or the final crises also showed weak but significant positive correlations with BMI in the overall sample (\u03c1 = 0.18 and 0.15, p &lt; 0.01 and &lt; 0.05 cutoff, respectively), and within the identified co-medication subgroups, including the valproate, carbamazepine, and no-modifier groups (\u03c1 = 0.19\u20130.26, all p &lt; 0.05). These associations accounted for a small proportion of the variance in overall time to withdrawal crisis (R2 = 0.02\u20130.07). Nevertheless, they translated into an additional 8\u201311 days of necessary monitored care among obese patients. Elimination duration was further prolonged in patients receiving valproate. Extended elimination was not associated with reduced withdrawal symptom severity.Conclusions:Among patients undergoing detoxification for BZD dependence, higher BMI was associated with prolonged drug elimination and a longer duration of recurring withdrawal crises, without attenuation of symptom severity. Although the observed associations were modest and potentially influenced by confounding factors, they suggest that overweight patients may require extended monitoring during detoxification. Prospective studies are needed to confirm these findings. To reduce the risk of delayed withdrawal crises and maintain treatment within reasonable time frames, minimizing excessive BZD accumulation through laboratory-guided dose adjustment is recommended.<\/jats:p>","DOI":"10.31083\/ap51895","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:23:51Z","timestamp":1788438231000},"source":"Crossref","is-referenced-by-count":0,"title":["Longer Duration of Drug Elimination and Withdrawal Symptoms in Overweight Patients Undergoing Detoxification for Benzodiazepine Dependence"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-1901","authenticated-orcid":true,"given":"Anna","family":"Basi\u0144ska-Szafra\u0144ska","sequence":"first","affiliation":[{"name":"Department of Prevention and Treatment of Addictions, Institute of Psychiatry and Neurology in Warsaw, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Archives of General Psychiatry. 1990; 47: 899\u2013907.","DOI":"10.1001\/archpsyc.1990.01810220015002"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Filmer S, Maidment I. Facilitators and barriers to the deprescribing of benzodiazepines and Z-drug hypnotics in patients under 65 on adult mental health wards. Scientific Reports. 2025; 15: 41420.","DOI":"10.1038\/s41598-025-25261-4"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR. Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PloS One. 2023; 18: e0285584.","DOI":"10.1371\/journal.pone.0285584"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Chan WL, Wood DM, Dargan PI. Prescription medicine misuse in the Asia-Pacific region: An evolving issue? British Journal of Clinical Pharmacology. 2021; 87: 1660\u20131667.","DOI":"10.1111\/bcp.14638"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Network Open. 2019; 2: e187399.","DOI":"10.1001\/jamanetworkopen.2018.7399"},{"key":"ref6","unstructured":"NHS England. Health and care of people with learning disabilities, experimental statistics 2021 to 2022. Chapter: Prescribing. 2022. Available at: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-and-care-of-people-with-learning-disabilities\/experimental-statistics-2021-to-2022 (Accessed: 29 April 2026)."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Luta X, Bagnoud C, Lambiris M, Decollogny A, Eggli Y, Le Pogam MA, et al. Patterns of benzodiazepine prescription among older adults in Switzerland: a cross-sectional analysis of claims data. BMJ Open. 2020; 10: e031156.","DOI":"10.1136\/bmjopen-2019-031156"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lee KJ, Wei Y, Leung SM, Huang C, Yiu HH, Deng EK, et al. A decade of benzodiazepine and Z-drug use in Hong Kong: a longitudinal study. The Lancet Regional Health\u2013Western Pacific. 2025; 59: 101591.","DOI":"10.1016\/j.lanwpc.2025.101591"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska A. Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring. European Journal of Clinical Pharmacology. 2021; 77: 795\u2013808.","DOI":"10.1007\/s00228-020-03048-y"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska A. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking. European Journal of Clinical Pharmacology. 2022; 78: 101\u2013110.","DOI":"10.1007\/s00228-021-03205-x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska A. Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure. European Journal of Clinical Pharmacology. 2022; 78: 1833\u20131841.","DOI":"10.1007\/s00228-022-03388-x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with benzodiazepines and related substances. Deutsches Arzteblatt International. 2015; 112: 1\u20137.","DOI":"10.3238\/arztebl.2015.0001"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J\u00d8, Lindschou J, Gluud C, Glenth\u00f8j BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. The Cochrane Database of Systematic Reviews. 2018; 3: CD011481.","DOI":"10.1002\/14651858.CD011481.pub2"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. Journal of Clinical Psychopharmacology. 1999; 19: 12S\u201316S.","DOI":"10.1097\/00004714-199912002-00003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Archives of General Psychiatry. 1991; 48: 448\u2013452.","DOI":"10.1001\/archpsyc.1991.01810290060012"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, et al. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. Journal of Psychopharmacology (Oxford, England). 2017; 31: 1369\u20131373.","DOI":"10.1177\/0269881117714050"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Harris JT, Roache JD, Thornton JE. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention. Alcohol and Alcoholism (Oxford, Oxfordshire). 2000; 35: 319\u2013323.","DOI":"10.1093\/alcalc\/35.4.319"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology. 1982; 13: 553\u2013560.","DOI":"10.1111\/j.1365-2125.1982.tb01421.x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clinical Neuropharmacology. 2005; 28: 96\u2013101.","DOI":"10.1097\/01.wnf.0000154221.37887.73"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Gunes A, Bilir E, Zengil H, Babaoglu MO, Bozkurt A, Yasar U. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic & Clinical Pharmacology & Toxicology. 2007; 100: 383\u2013386.","DOI":"10.1111\/j.1742-7843.2007.00061.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British Journal of Clinical Pharmacology. 2001; 52: 547\u2013553.","DOI":"10.1046\/j.0306-5251.2001.01474.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Zang YN, Guo W, Niu MX, Bao S, Wang Q, Wang Y, et al. Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder. European Journal of Clinical Pharmacology. 2022; 78: 405\u2013418.","DOI":"10.1007\/s00228-021-03246-2"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Knibbe CAJ, Brill MJE, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annual Review of Pharmacology and Toxicology. 2015; 55: 149\u2013167.","DOI":"10.1146\/annurev-pharmtox-010814-124354"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Greenblatt DJ, Arendt RM, Abernethy DR, Giles HG, Sellers EM, Shader RI. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. British Journal of Anaesthesia. 1983; 55: 985\u2013989.","DOI":"10.1093\/bja\/55.10.985"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Bruno CD, Harmatz JS, Duan SX, Zhang Q, Chow CR, Greenblatt DJ. Effect of lipophilicity on drug distribution and elimination: Influence of obesity. British Journal of Clinical Pharmacology. 2021; 87: 3197\u20133205.","DOI":"10.1111\/bcp.14735"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. Journal of Clinical Pharmacology. 1983; 23: 369\u2013376.","DOI":"10.1002\/j.1552-4604.1983.tb02750.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zarezadeh M, Saedisomeolia A, Shekarabi M, Khorshidi M, Emami MR, M\u00fcller DJ. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. European Journal of Nutrition. 2021; 60: 2905\u20132921.","DOI":"10.1007\/s00394-020-02421-y"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska AR. Pharmacokinetics-Driven Individualized Detoxification Procedure in Patients Dependent on Benzodiazepines and Other GABA-A Receptor Modulators. European Addiction Research. 2025; 31: 264\u2013273.","DOI":"10.1159\/000547221"},{"key":"ref29","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization: Geneva. 1993."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Achterbergh R, Lammers LA, van Nierop S, Kl\u00fcmpen HJ, Soeters MR, Math\u00f4t RAA, et al. A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects. Expert Opinion on Drug Metabolism & Toxicology. 2016; 12: 715\u2013720.","DOI":"10.1080\/17425255.2016.1192126"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, et al. A Review of Food-Drug Interactions on Oral Drug Absorption. Drugs. 2017; 77: 1833\u20131855.","DOI":"10.1007\/s40265-017-0832-z"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Gamble JA. Proceedings: Some factors influencing the absorption of diazepam. Proceedings of the Royal Society of Medicine. 1975; 68: 772.","DOI":"10.1177\/003591577506801219"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Niederberger E, Parnham MJ. The Impact of Diet and Exercise on Drug Responses. International Journal of Molecular Sciences. 2021; 22: 7692.","DOI":"10.3390\/ijms22147692"},{"key":"ref34","unstructured":"Sellers EM. Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ: Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 1988; 139: 113\u2013120."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. Journal of Clinical Psychopharmacology. 1989; 9: 412\u2013416.","DOI":"10.1097\/00004714-198912000-00005"},{"key":"ref36","unstructured":"Roche Diagnostics. Serum Benzodiazepines (SBENZ) #20766690322, Method sheet v.8. Roche Diagnostics GmbH, Mannheim. 2015. Available at: https:\/\/pim-eservices.roche.com\/eLD\/api\/downloads\/ebe3f7c2-d178-e511-f1bd-00215a9b3428?countryIsoCode=pl (In Polish) (Accessed: 15 November 2022)."},{"key":"ref37","unstructured":"Statsoft Inc. Statistica 13.3.0. 2017. Available at: https:\/\/www.statsoft.pl\/statistica_13_3\/ (Accessed: 15 December 2024)."},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Brenner PM, Wolf B, Rechlin T, Kauert G, R\u00fcther E, Hippius H. Benzodiazepine dependence: detoxification under standardized conditions. Drug and Alcohol Dependence. 1991; 29: 195\u2013204.","DOI":"10.1016\/0376-8716(91)90049-5"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska AR. High levels of benzodiazepines after treatment of moderate alcohol withdrawal syndrome: the problem of incomplete detoxification. Postepy Psychiatrii Neurologii. 2022; 31: 1\u20135.","DOI":"10.5114\/ppn.2022.114662"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. Journal of Clinical Psychopharmacology. 2018; 38: 172\u2013179.","DOI":"10.1097\/JCP.0000000000000861"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR. Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. Journal of Clinical Psychopharmacology. 2018; 38: 289\u2013295.","DOI":"10.1097\/JCP.0000000000000892"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Denis C, Fats\u00e9as M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. The Cochrane Database of Systematic Reviews. 2006; CD005194.","DOI":"10.1002\/14651858.CD005194.pub2"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018; 51: 9\u201362.","DOI":"10.1055\/s-0043-116492"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Apovian CM, Bruno CD, Kyle TK, Chow CR, Greenblatt DJ. Incomplete Data and Potential Risks of Drugs in People with Obesity. Current Obesity Reports. 2023; 12: 429\u2013438.","DOI":"10.1007\/s13679-023-00532-1"}],"container-title":["Alpha Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/4\/10.31083\/AP51895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:24:00Z","timestamp":1788438240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/4\/10.31083\/AP51895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2757-8038(26)02212-3"],"URL":"https:\/\/doi.org\/10.31083\/ap51895","relation":{},"ISSN":["2757-8038"],"issn-type":[{"value":"2757-8038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"51895"}}